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 1 
Three or more BoNTA interventions are associated with altered medial gastrocnemius 1 
volume and echo-intensity in children with spastic cerebral palsy 2 
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ABBREVIATIONS 1 
SCP  Spastic cerebral palsy 2 
MG  Medial gastrocnemius 3 
MRI  Magnetic resonance imaging 4 
TD  Typically developing 5 
GMFCS  Gross motor function classification system 6 
BoNTA  Botulinum neurotoxin-A 7 
3DfUS  Three-dimensional freehand ultrasonography 8 
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AIM Children with spastic cerebral palsy (SCP) have smaller medial gastrocnemius (MG) 1 
volumes and higher echo-intensity values with respect to typical developing (TD) peers. These 2 
alterations associate with the Gross Motor Function Classification System (GMFCS). Botulinum 3 
neurotoxin A (BoNTA) interventions are a common treatment with proven functional outcomes. 4 
This cross-sectional investigation evaluates whether recurrent BoNTA interventions to the MG 5 
have an additional influence on muscle morphology, beyond GMFCS level. 6 
METHOD A TD-cohort (n=67, median age 9:11 (7:10-11:6)), a SCP-cohort naive to BoNTA 7 
interventions (No-BoNTA n=19, median age 9:3 (8:5-10:10)) and a SCP-cohort with a minimum 8 
of three recurrent BoNTA interventions to the MG (BoNTA n=19, 9:8 (7:3-10:7)) were recruited. 9 
Three-dimensional freehand ultrasound was used to estimate MG volume normalised to body 10 
mass, and echo-intensity. 11 
RESULTS Normalised MG volume and echo-intensity significantly differed between the two SCP 12 
cohorts (p≤0.050), with the BoNTA cohort having larger alterations. Associations between 13 
normalised MG volume and echo-intensity were highest in the No-BoNTA cohort, followed by 14 
the BoNTA cohort. Multiple regression analyses revealed that both GMFCS level and BoNTA 15 
intervention history significantly associated with smaller normalised MG volume and higher 16 
echo-intensity.  17 
INTERPRETATION Recurrent BoNTA interventions may induce alterations to MG volume and 18 
echo-intensity, beyond the natural history of the SCP pathology. 19 
SHORTENED TITLE Altered muscle morphology due to BoNTA 20 
WHAT THIS PAPER ADDS 21 
 SCP MG volumes are smaller with higher echo-intensities compared with TD 22 
 The alterations in the BoNTA cohort are larger than in the No-BoNTA cohort 23 
 GMFCS level and BoNTA history significantly associate with smaller MG volume and 24 
higher echo-intensity  25 
 4 
Muscles are the motor components of the body, with their rate of growth in the early years of life 1 
crucial for achieving developmental milestones, such as crawling, standing and walking. The 2 
force-generating capabilities of a muscle are largely dependent on its gross-morphological 3 
properties, such as volume. In children with spastic cerebral palsy (SCP), fewer satellite cells, 4 
overlengthened sarcomeres and abnormal motor unit recruitment and activation characterise the 5 
underlying pathophysiology of muscle growth and joint contractures.1,2 Consequently, deficits in 6 
medial gastrocnemius (MG) growth have been reported,3–5 a muscle with an important power 7 
generation function during walking.6 To confound matters, magnetic resonance imaging (MRI) 8 
revealed adipose tissue replacing contractile tissue in the lower limb muscles of children and 9 
adolescents with bilateral SCP.7,8 This was corroborated using B-mode ultrasound, where the MG 10 
appeared hypo-echoic with respect to typically developing (TD) peers.9,10 Two of these 11 
investigations also identified that the extent of changes within the muscle associated with gross 12 
motor function classification system (GMFCS) level,8,9 as did muscle volume,4 inferring that muscle 13 
activation and level of functional ability play a meaningful role in these alterations. It is therefore 14 
likely that there will be a high association between the volume and echo-intensity of the MG in 15 
SCP individuals.  16 
The use of botulinum neurotoxin A (BoNTA) is a common treatment modality in children with 17 
SCP, targeting the hyperactive stretch reflex.11 The short-term chemo-denervation at the pre-18 
synaptic membrane, combined with serial-casting and physiotherapy, has been shown to 19 
improve gait function.12 Its use is not without concern, as discussed in a review on muscle 20 
deformity in children with SCP.13 Attempts to address the veracity of these concerns have been 21 
undertaken in several longitudinal investigations, where MG volume was evaluated following 22 
BoNTA interventions. A reduction was reported five weeks post-infiltration,14 but a six month 23 
follow-up with a targeted strength training protocol revealed eventual gains in both volume and 24 
strength.15 A long-term investigation one year post intervention found absolute MG volume to 25 
increase in two cohorts of BoNTA-naive SCP children.16 However, the use of absolute volume, 26 
instead of a normalised parameter, might have biased the results (not taking the interim one 27 
 5 
year of growth into consideration). Based on their reported data, normalising mean MG volume 1 
to mean body mass revealed a mean decrease from 1.70ml/kg to 1.62ml/kg in one cohort, and a 2 
mean increase from 1.54ml/kg to 1.56ml/kg in the other cohort.16 This strengthens the notion 3 
that BoNTA interventions may lead to reduced MG volume in the long-term. These insightful 4 
findings regarding the use of BoNTA are of interest to the wider clinical community, but there 5 
are some limitations to consider. Firstly, in two of the investigations,14,15 the cohorts had 6 
received an unspecified number of previous BoNTA interventions, providing a challenge to 7 
differentiate the influence of previous BoNTA interventions from the natural history of the SCP 8 
pathology. Secondly, muscle volume does not provide insight into alterations to the 9 
intramuscular composition, where a high recurrence of BoNTA infiltrations, or BoNTA 10 
infiltrations delivered with a short interval, associated with neurogenic atrophy.17 In addition, 11 
the number of BoNTA infiltrations to the MG significantly associated with type-1 fibre loss and 12 
type-2 fibre predominance, which may impair long-term muscle function.17 Therefore, future 13 
investigations evaluating the influence of BoNTA interventions should also consider alterations 14 
to both contractile (myo-fibers) and non-contractile (adipose/connective tissue) tissue within 15 
the injected muscle. 16 
Three-dimensional freehand ultrasonography (3DfUS) is a static-condition measurement 17 
modality that enables anatomical regions to be reconstructed in three-dimensions. It consists of a 18 
B-mode ultrasound and motion-tracking system, where the spatial coordinates of reflective 19 
markers rigidly affixed to the ultrasound probe are recorded for each acquired image.18 It requires 20 
minimal acquisition time, which is favourable in measurements with younger children. Using 21 
3DfUS, alterations to MG volume and echo-intensity in children with SCP were reported.10,19,20 22 
When visualising healthy  muscles, non-contractile properties such as tendons and adipose tissue 23 
appear lighter (hyper-echoic), whilst fluid and bones appear darker (hypo-echoic). A biopsy 24 
analysis revealed a high association between echo-intensity and proportion of fibrous tissue in 25 
the extracted sample,21 whilst MRI revealed high associations between echo-intensity of the MG 26 
 6 
with the quantity of intramuscular adipose tissue.22 These findings suggest that echo-intensity can 1 
be used as an indirect quantification of alterations to the properties within a muscle. 2 
This investigation will explore the influence of BoNTA interventions on the MG volume and echo-3 
intensity in individuals SCP. A cross-sectional design will be employed, where two SCP cohorts are 4 
identified, 1) a minimum of three BoNTA interventions (BoNTA cohort) and, 2) naive to BoNTA 5 
interventions (No-BoNTA cohort). A matched TD control cohort will also be identified. The first 6 
aim is to compare normalised MG volumes and echo-intensities between the two SCP cohorts, and 7 
with respect to the TD cohort. The hypothesis states that both SCP cohorts have significantly 8 
smaller MG volumes and higher echo-intensities with respect to the TD cohort, whilst the 9 
alterations in the BoNTA cohort will be significantly greater with respect to the No-BoNTA cohort. 10 
The second aim is to explore the association between MG volume and echo-intensity in all three 11 
cohorts. The hypothesis states that there will be no meaningful association in the TD cohort, but 12 
strong negative associations in the SCP cohorts. The third aim is to explore if BoNTA intervention 13 
history significantly associates with smaller MG volume and higher echo-intensity, in addition to 14 
GMFCS level. The hypothesis states that both GMFCS level and BoNTA intervention history will 15 
significantly associate towards smaller MG volume and higher echo-intensity. 16 
METHOD 17 
Participants 18 
Data collection was performed as part of an ongoing research project (muscle morphology and 19 
function in spastic cerebral palsy), where TD children and adolescents, as well as those diagnosed 20 
with SCP, were recruited through the clinical motion analysis laboratory at the University Hospital 21 
of Leuven between January 2015 to September 2017. The initial diagnosis of SCP was confirmed 22 
by a neuro-paediatrician, based on MRI imaging of the brain and clinical examination. To minimise 23 
bias and ensure appropriate matching of two SCP cohorts, the following inclusion criteria were 24 
applied to all previously acquired data: a) between 5-16 years of age, b) GMFCS levels I-II, c) no 25 
previous orthopaedic or neurological surgery, d) naive to BoNTA interventions or at least six 26 
 7 
months after a third or more recurrent BoNTA intervention. Following this retrospective analysis, 1 
42 children and adolescents with SCP were identified that fulfilled the criteria. A BoNTA and No-2 
BoNTA cohort were then defined, matched in order of GMFCS level, topographical paresis, body 3 
mass and age. This resulted in two groups of 19 participants, with the remaining four participants 4 
excluded. The earliest clinical examination for each participant was also reviewed to ensure 5 
comparable baseline clinical characteristics for joint range of motion, spasticity and strength at 6 
the ankle (Table S1, online supporting information). The BoNTA cohort had a median five previous 7 
interventions (IQR 3-6), with a median frequency of 12 months between interventions (IQR 10-8 
16). All 38 participants were under the same multi-disciplinary management, whilst the BoNTA 9 
cohort all followed the same post-BoNTA treatment protocol, consisting of serial casting and 10 
physiotherapy.23 An overview of the quantity and timing of the BoNTA interventions can be found 11 
in Figure S1 (online supporting information). A TD cohort was also defined, matched with respect 12 
to mass and age, resulting in 67 participants (Table I). The experimental protocol was approved 13 
by the local Ethical-Committee (s57234), whilst written informed consent was acquired from all 14 
parents/guardians and children over the age of 12. 15 
Instrumentation 16 
A 3DfUS method was utilised for this investigation.18 This consisted of a Telemed-Echoblaster 128 17 
Ext-1Z B-mode ultrasound system with a 5.9cm 10MHz linear US probe (HL9.0/60/128Z), and an 18 
OptiTrack V120:Trio motion-tracking system with three fixed optical cameras (NaturalPoint, 19 
USA). As echo-intensity is influenced by the ultrasound parameters, care was taken to ensure they 20 
remained the same for all of the acquisitions (frequency, 10MHz; depth, 5cm; focus, 1.8-2.8cm; 21 
gain, 46%; dynamic range, 44dB and unaltered time-gain compensation), whilst images were 22 
recorded at 30Hz. The motion-tracking system has a 1mm spatial resolution, and images were 23 
recorded at 120Hz. To acquire synchronized data, a signal trigger was utilised.18 24 
Acquisition 25 
 8 
For each SCP participant, the most affected leg was measured according to their most recent 1 
clinical examination, whilst a coin-flip determined the measured leg in the TD cohort. Age and 2 
body mass was recorded for each participant. In prone lying, a triangular cushion was placed 3 
under the shank to provide approximately 25 degrees of knee flexion, and a cushioned belt was 4 
strapped over the thigh to prevent movement of the leg (Figure 1). Two physiotherapists 5 
experienced with 3DfUS and visual identification of the MG acquired all of the data, using sufficient 6 
gel to avoid excess pressure on the leg. Care was taken to hold the ultrasound probe perpendicular 7 
to the deep aponeurosis of the MG throughout the acquisition, enhancing the visibility of the 8 
muscle border and minimising erroneous echoes. The ultrasound probe was moved in a 9 
transverse orientation over the condyles of the knee, distally along the MG until the end of the 10 
calcaneus. In cases of visually detected muscle contraction or movement of the leg, the acquisition 11 
was repeated. Two acquisitions were acquired for each participant.  12 
Processing 13 
Three-dimensional reconstructions were created using a custom-made software package,18 and 14 
processed using HOROS (www.horosproject.org). The same physiotherapist performed all of the 15 
processing using the first of the two acquisitions. The MG was defined from the inferior margin of 16 
the medial condyle of the tibia, until the most distal visible image of the MG.24 Volume and echo-17 
intensity were estimated by drawing equally spaced transverse plane segmentations along the 18 
inside of the muscle border, summing 10% of all the available ultrasound images of the MG. An 19 
interpolation was applied to create segmentations in the remaining 90% of images. This reduced 20 
the time required to extract MG volume and echo-intensity, whilst also maintaining sufficient 21 
reliability (standard error of measurement values for estimating MG volume and echo-intensity 22 
are 2.6ml and 3.3 values, respectively).20 MG volume was reported in ml, and echo-intensity on an 23 
8-bit greyscale (0-255 values). For the latter, the value 0 represented black and 255 white, with 24 
in-between values 254 shades of grey. To enable inter-participant comparisons, MG volume was 25 
 9 
normalised to body mass, reported as ml/kg.3–5 An illustration of the three-dimensional 1 
acquisition and processing can be found in Figure 1. 2 
Statistical analysis 3 
Data were analysed in SPSS version 22 (SPSS, Inc., Chicago, Illinois). Normal distribution of the 4 
primary outcome parameters was accepted by plotting the data and visually inspecting the 5 
symmetry of the histogram. In addition, the data was also reported as median and interquartile 6 
range, revealing the extent of skewness in each parameter. Equality of variance was assessed 7 
using Levene’s test (p≥0.050), and treated accordingly. The threshold for statistical significance 8 
was two-tailed. To determine if the SCP cohorts differed at the time of their earliest clinical 9 
examination, age, ankle dorsiflexion (with the knee extended), modified Ashworth score, modified 10 
Tardieu scale and manual muscle testing of the plantar flexors were compared using an 11 
independent samples Mann-Whitney U test (p≤0.050). To answer the first hypothesis, a one-way 12 
analysis of variance and Tukey HSD post-hoc test compared age, body mass, absolute and 13 
normalised MG volume, and echo-intensity between the three cohorts. To answer the second 14 
hypothesis, a Pearson’s correlation was used to determine the strength of the associations 15 
between echo-intensity and normalised MG volume in the two SCP and TD cohort (0-0.2, poor; 16 
0.21-0.4, fair; 0.41-0.6, moderate; 0.61-0.8, good and 0.81-1.0, very good).25 To answer the third 17 
hypothesis, multiple regression analyses were performed on the combined SCP cohorts. Both 18 
GMFCS level and BoNTA intervention history (No-BoNTA cohort = group 0, BoNTA cohort = group 19 
1) were entered as independent variables to determine if they both significantly associate with 20 
normalised MG volume and echo-intensity. The adjusted r2 and p-value of the model, and p-value 21 
of each independent variable was calculated. 22 
RESULTS 23 
The Mann-Whitney U test revealed no significant differences in age, body mass, or outcome 24 
parameters between the two SCP cohorts at their earliest clinical examination, except for 25 
maximum ankle dorsiflexion (p=0.030) (Table SI). The Tukey HSD post-hoc test revealed no 26 
 10 
significant differences between the three cohorts for age (F2,102=.023; p=.977) or body mass 1 
(F2,102=1.237; p=.295). Statistically significant differences were found for all the primary outcome 2 
parameters, except absolute MG volume between the SCP cohorts (Table II). 3 
In the BoNTA cohort, echo-intensity had a positive significant fair association with the number of 4 
previous BoNTA interventions (r=.58, p=.009), and a negative non-significant fair association with 5 
the frequency between recurrent BoNTA interventions (r=-.41, p=.078). Echo-intensity had a 6 
negative significant fair, moderate and good association with normalised MG volume in the TD, 7 
BoNTA and No-BoNTA cohorts, respectively (Table II, Figure 2.) 8 
The multiple regression analyses revealed that both GMFCS level and BoNTA intervention history 9 
significantly associate towards explaining both echo-intensity (adjusted r2=.64, model p0.001, 10 
GMFCS level p0.001, BoNTA history p0.001), and normalised MG volume (adjusted r2=.52, 11 
p0.001, GMFCS level p0.001, BoNTA history p=0.003). 12 
DISCUSSION 13 
The first aim of this investigation was to compare normalised MG volume and echo-intensity 14 
between a SCP cohort with a minimum of three recurrent BoNTA interventions, a SCP cohort naive 15 
to BoNTA interventions, and a control TD cohort. The first finding was that the normalised MG 16 
volume of the TD cohort was comparable to that of previous reported values in literature,4,5,24 and 17 
significantly larger than the normalised MG volumes of both SCP cohorts. The SCP BoNTA cohort 18 
had the largest deficits in normalised MG volume, which were also significantly smaller with 19 
respect to the No-BoNTA cohort. Therefore, it may be that the repeated sessions of BoNTA 20 
interventions further inhibit muscle growth, beyond the natural history of the pathology. 21 
Similarly, both SCP cohorts had significantly higher MG echo-intensity values with respect to the 22 
TD cohort, with the BoNTA cohort also presenting with significantly higher echo-intensity values 23 
with respect to the No-BoNTA cohort. Therefore, the first hypothesis, stating that both SCP cohorts 24 
have smaller normalised volumes and higher echo-intensities with respect to the TD cohort, was 25 
confirmed. The employed 3DfUS technique has previously been used to quantify higher MG echo-26 
 11 
intensity values in children with SCP,10,20 strengthening the concept that not all of the measured 1 
muscle volume is functional contractile or connective tissue. This may be due to a higher 2 
percentage of intramuscular fat,7,8 and changes to the collagen content, like the extracellular 3 
matrix.26 It remains to be seen at what age these alterations occur, but the importance of 4 
stimulating cross-sectional muscle growth as early as possible is imperative for maximising long-5 
term muscle function.2  6 
The second aim of this investigation was to explore the association between echo-intensity with 7 
normalised MG volume. In all three cohorts, significantly negative associations were found, with 8 
the strongest in the No-BoNTA cohort (r=-.72), followed by the BoNTA (r=-.54) and TD cohorts 9 
(r=-.27). Therefore, the second hypothesis, stating that there will be no meaningful association in 10 
the TD cohort, but strong negative associations in the SCP cohorts, was confirmed. The negative 11 
association in the TD cohort may be explained by attenuation of the ultrasound beam due to the 12 
much larger MG muscles, leading to a reduction in returning echoes. The high association in the 13 
No-BoNTA cohort is very informative, as it suggests that alterations to normalised MG volume and 14 
echo-intensity may be explained by the natural history of the pathology, likely a lack of 15 
myofibrillar growth.13 However, the weaker association in the BoNTA cohort infers that 16 
something beyond the natural history of the pathology is inducing additional alterations to 17 
normalised MG volume and echo-intensity. This may be explained by BoNTA interventions 18 
targeting an increase in passive ankle joint resistance due to spasticity, when reduced muscle 19 
growth and altered tissue properties may have been more culpable. The resulting chemo-20 
denervation induced atrophy,14 combined with ankle joint immobilisation (serial casting), could 21 
have triggered the additional alterations identified in the BoNTA cohort. Quantifying ankle joint 22 
resistance and muscle activation in an objective and quantitative manner, and evaluating the 23 
individual influence of both BoNTA and serial casting, may help to provide more insight into what 24 
is happening to the MG and the ankle joint.2,27,28 Smaller MG volumes will also likely result in a 25 
reduced capacity to generate sufficient active force, but the consequence of higher echo-intensity 26 
values is less clear. The understanding of the implications may be supported by earlier research. 27 
 12 
An increase in passive tissue stiffness of the SCP MG has been identified, quantified according to 1 
the shear wave velocity of ultrasound elastography.26 A subsequent investigation found that 2 
differences in shear wave velocity between the non-paretic and the paretic muscles of individuals 3 
with stroke were strongly associated with differences in echo intensity.26 Based on this, higher MG 4 
echo-intensity may be indicative of an increase in passive stiffness of the muscle properties. If so, 5 
it would be of great interest to determine whether the MG is able to increase in length following 6 
BoNTA and serial casting, or whether it is inhibited by the altered tissue composition. 7 
Additionally, the ability to recruit and activate motor units is also a known impairment in children 8 
and adolescents with SCP.1 Exploring if higher echo-intensity values with measures are related to 9 
reduced isometric force- and rate of torque-generation, as seen in sarcopenia populations,29 10 
would also provide another clinical meaning to higher echo-intensity values in individuals with 11 
SCP. 12 
The third aim of this investigation was to explore whether in addition to GMFCS level and age, 13 
BoNTA intervention history significantly associates with alterations in normalised MG volume 14 
and echo-intensity. GMFCS level was included, as it has previously been shown to associate with 15 
MG volume and echo-intensity, representing the natural history of the SCP pathology in the No-16 
BoNTA cohort.4,8,9,24  The multiple regression analyses revealed that both BoNTA history and 17 
GMFCS level significantly associate with both echo-intensity and normalised MG volume in the 18 
combined SCP cohort, thereby confirming the third hypothesis. To the best of our knowledge, this 19 
is one of the strongest reported findings of alterations to MG morphology due to recurrent BoNTA 20 
interventions. This is also supported from a clinical perspective, where it was suggested that the 21 
efficacy of BoNTA interventions to improve overall functional ability in children with SCP may 22 
diminish after three recurrent treatments.23 However, as BoNTA interventions have been 23 
reported to yield functional benefits, at least in the short-term, it is worthwhile to determine if 24 
treatment goals can still be attained with a smaller BoNTA dosage, perhaps calculated with respect 25 
to the normalised MG volume or echo-intensity, instead of body mass.30  26 
 13 
Limitations 1 
Determining the effects of an intervention is preferable with a longitudinal investigation design. 2 
However, evaluating the long-term influence of BoNTA interventions on muscle morphology 3 
would span the course of many years, with various feasibility issues. Therefore, this investigation 4 
utilised a cross-sectional design, where careful attention was placed on matching two SCP cohorts 5 
with differing treatment histories (BoNTA/No-BoNTA). Based on the ankle impairments from 6 
their earliest clinical examinations, we did not identify any statistically significant differences, 7 
aside from slightly less dorsiflexion in the BoNTA cohort, which may have been due to insufficient 8 
power. Nonetheless, it remains unclear why the treatment histories differed, but it is likely related 9 
to a more comprehensive evaluation of impairments. This would also include the knee and hip 10 
joint levels, degree of pathological gait, and also considering both patient and family preferences 11 
with respect to treatment goals.11 Furthermore, as a consequence of the research design, this 12 
investigation is unable to delineate between the individual influence of BoNTA infiltrations, and 13 
the subsequent protocol of serial casting and physiotherapy. As mentioned earlier, there was a 14 
mild attenuation of the US beam when visualising the largest MG muscles in the TD cohort. This 15 
effect seemed confined to the TD cohort, as the largest MG volume in the SCP cohort was around 16 
the mean of the TD cohort. Future investigations may aim to negate this problem by altering the 17 
ultrasound time-gain-compensation settings, however that may introduce new challenges for 18 
inter-participant comparisons of echo-intensity. Another possibility is to apply a correction to the 19 
ultrasound images that takes into consideration the thickness of the subcutaneous tissue and 20 
depth of the muscle.22  21 
CONCLUSION 22 
This investigation identified that a history of three or more BoNTA interventions has an additional 23 
negative influence on normalised MG volume and echo-intensity, beyond the natural history of 24 
the SCP pathology. This is a novel finding and warrants further confirmation. It may be that BoNTA 25 
interventions associate with differences seen at the muscle (smaller volume, higher echo-26 
 14 
intensity), as we cannot conclude whether they are the cause of the altered muscle properties. 1 
However, as a lack of muscle growth and increased passive stiffness seem to be key factors in the 2 
presence of joint contractures, it is important to be aware of the potential risks of recurrent 3 
BoNTA interventions in individuals with spastic cerebral palsy. 4 
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Table I. Overview of participant characteristics 
TD, typically developing; SCP, spastic cerebral palsy; SD, standard deviation; BL, bilateral; UL, 
unilateral; GMFCS, gross motor function classification system; NA, not applicable 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cohorts 
TD (n=67) SCP No-BoNTA (n=19) SCP BoNTA(n=19) 
Median (IQR) 
Age (y:mo) 9:11 (7:10-11:6) 9:8 (7:3-10:7) 9:3 (8:5-10:10) 
Mass (kg) 29.6 (24.3-39.8) 29 (20.5-42) 26.5 (22.9-29.7) 
Sex 43M / 24F 10M / 9F 13M / 6F 
Topographic Paresis NA 9BL / 10UL 9BL / 10UL 
GMFCS levels NA 13 I / 6 II 13 I / 6 II 
 19 
 
Table II. Overview and comparison of the primary outcome parameters between all three cohorts, and the associations between medial 
gastrocnemius mean echo-intensity and normalised muscle volume. 
 
 
 
 
 
 
 
 
 
 
 
 
TD, typically developing; SCP, spastic cerebral palsy; NoBoNTA, cohort naïve to previous BoNTA interventions; BoNTA, cohort with a minimum of 
three previous BoNTA interventions 
Outcome 
Parameters 
TD 
(n=67) 
SCP No-BoNTA 
(n=19) 
SCP BoNTA 
(n=19) 
TD 
vs. 
SCP No-BoNTA 
TD 
vs. 
SCP BoNTA 
SCP No-BoNTA 
vs. 
SCP BoNTA 
 Median (IQR) Independent samples t-test (p0.050) 
Echo-intensity 
(0-255) 
99.8 (93.6-106.5) 117.1 (110.7-121.2) 124.9 (120.6-132.9) 0.001 0.001 0.004 
MG volume 
(ml) 
62.0 (49.7-81.8) 44.4 (33.7-58.9) 31.5 (25.3-44.0) =0.004 0.001 0.140 
Normalised MG 
volume (ml/kg) 
2.1 (1.8-2.3) 1.5 (1.3-1.7) 1.2 (1.0-1.6) 0.001 0.001 0.032 
Pearson Correlation 
(echo-intensity vs. normalised MG volume) 
TD (n=67) SCP NoBoNTA (n=19) SCP BoNTA (n=19) 
r -.27 -.72 -.54 
p value (significance at 0.050) 0.025 0.001 0.016 
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Figure 1: Upper image: An example of the 3DfUS measurement acquisition with the instrumented US probe. Centre image: A sagittal plane image 
extracted from the 3D reconstruction. Lower image: Examples of muscle border segmentations in the transverse plane images, and the resulting 
interpolated 3D reconstruction of the medial gastrocnemius. MFC, medial femoral condyle; MTC, medial tibial condyle; MTJ, muscle-tendon junction; 
C, calcaneus; MG, medial gastrocnemius.
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Figure 2: No-BoNTA, cohort naive to previous BoNTA interventions; BoNTA, cohort with a minimum of three previous BoNTA interventions; 
TD, typically developing control cohort. 
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SUPPLEMENTARY INFORMATION 
 
Table SI – Comparisons between the two spastic cerebral palsy cohorts at the time of their 
earliest clinical examinations. 
 
TD, typically developing; SCP, spastic cerebral palsy; NoBoNTA, cohort naïve to previous BoNTA 
interventions; BoNTA, cohort with a minimum of three previous BoNTA interventions; Max DF, 
maximum dorsiflexion with the knee extended; MAS, modified Ashworth scale; MTS, modified 
Tarideu scale; MMT - PF, manual muscle testing of the plantar flexors. 
 
 
 
 
 
Figure S1: Each black dot represents a BoNTA intervention. The quantity of dots on each 
vertical line indicates the total number of previous BoNTA interventions to the medial 
gastrocnemius, whilst the gap in-between each dots indicates the time in months between 
recurrent interventions.  
 
 
Cohort 
TD 
(n=67) 
SCP No-BoNTA 
(n=19) 
SCP BoNTA 
(n=19) 
SCP No-BoNTA (n=19) vs. 
SCP BoNTA (n=19) 
 Median (Interquartile Range) p-value (significance at 0.050) 
Age (y:mo) - 6:2 (4:7 – 8:8) 5:3 (4:8-5:8) 0.093 
Max DF (°) - 10 (10 - 15) 5 (4 – 10) 0.030 
MAS - 2 (1.5 - 2) 2 (1.5 – 2) 0.523 
MTS (°) - -10 (-15 - -5) -10 (-16 - -5) 0.975 
MMT - PF - 3.6 (3.6 - 4) 3.6 (3.5 – 4) 0.684 
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